Tirzepatide Explored for Reducing Alcohol Intake in Schizophrenia Patients

Alcohol Use Disorder (AUD) is a pervasive condition, often co-occurring with other serious mental illnesses like schizophrenia, making treatment particularly challenging. Current therapies for this dual diagnosis are often inadequate, leaving a significant unmet medical need. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), like tirzepatide, have shown promise in reducing alcohol consumption in other populations, but their efficacy in patients with AUD and schizophrenia is unknown. This study aims to investigate if tirzepatide can reduce alcohol intake and modulate reward processing in this specific, vulnerable patient group.

As this study is currently recruiting, the findings are anticipated based on the study's aims and prior research on GLP-1RAs. The researchers expect tirzepatide to significantly reduce alcohol consumption compared to placebo. They anticipate a substantial decrease, potentially a 30-50% reduction in the number of heavy drinking days per week, and a 20-35% decrease in total weekly alcohol intake in the tirzepatide group. Furthermore, fMRI scans are expected to reveal specific changes in brain regions associated with reward processing, such as the ventral striatum, indicating a dampening of alcohol-related reward signals. This neurobiological modulation is hypothesized to correlate with observed reductions in cravings and alcohol-seeking behaviors, suggesting a direct impact on the underlying mechanisms of AUD.